A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immuno-therapy
Single-cell RNA-seq analysis of bioengineered human bone marrow leukemia chip established with human B-ALL cells (REH, ATCC), Human umbilical vein cells (HUVECs, Lonza), Human mesenchymal stem cells (hMSC, Lonza), Human Bone marrow mononuclear cells (STEMCELL Technologies), and Human MSC osteoblasts (Lonza) using the reported Leukemia-on-a-Chip method treated with Healthy donor derived CAR Tcells, Patient derived CAR T cells, Mock T cells, and or left non-treated. Overall design: Single-cell RNA-sequencing libraries of the retrived cells form the bioengineered human bone marrow leukemia chips. Healthy donor derived CAR Tcells, Patient derived CAR T cells, Mock T cells, and or Human bone marrow mononucelar cellswere also sequenced as controls